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Abstract
Background: Left ventricular (LV) hypertrophy and changes in LV geometry are associated with increased
cardiovascular mortality. Subjects with type 2 diabetes have an increased risk of such alterations in cardiac
morphology. We sought to assess the association of glycemic status and LV wall thickness measured by cardiac
magnetic resonance (CMR), and potential interactions of hypertension and diabetes.
Methods: CMR was performed on 359 participants from a cross-sectional study nested in a population-based
cohort (KORA FF4) free of overt cardiovascular disease. Participants were classified according to their glycemic
status as either control (normal glucose metabolism), prediabetes or type 2 diabetes. Segmentation of the left
ventricle was defined according to the American Heart Association (AHA) 16-segment model. Measurements of
wall thickness were obtained at end-diastole and analyzed by linear regression models adjusted for traditional
cardiovascular risk factors.
Results: LV wall thickness gradually increased from normoglycemic controls to subjects with prediabetes and
subjects with diabetes (8.8 ± 1.4 vs 9.9 ± 1.4 vs 10.5 ± 1.6 mm, respectively). The association was independent of
hypertension and traditional cardiovascular risk factors (β-coefficient: 0.44 mm for prediabetes and 0.70 mm for
diabetes, p-values compared to controls: p = 0.007 and p = 0.004, respectively). Whereas the association of glycemic
status was strongest for the mid-cavity segments, the association of hypertension was strongest for the basal
segments.
Conclusion: Abnormal glucose metabolism, including pre-diabetes, is associated with increased LV wall thickness
independent of hypertension.
Keywords: Cardiac magnetic resonance imaging, Prediabetes, Diabetes, Left ventricular wall thickness, 16-segment
model
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Background
Abnormal cardiac morphology, such as left ventricular
(LV) hypertrophy and altered geometry, represents a risk
factor for increased cardiovascular mortality and
morbidity [1, 2].
Increased LV wall thickness is considered as an adaptive
response to augmented wall stress caused by pressure
overload. Short-term increase in wall thickness can there-
fore be regarded as a beneficial adaptation in order to
maintain oxygen demand and contractile function of the
heart [3]. However, a persistent increase in wall thickness
leads to impaired myocardial relaxation and subsequently
to decreased diastolic function, [4] which is associated
with diastolic heart failure and other adverse cardiovascu-
lar outcomes [5]. The exact pathophysiological pathways
of the transition from compensatory response to a detri-
mental chronic condition are not yet fully understood.
Chronic hypertension and the resulting increased
hemodynamic load are a major risk factor for cardiac re-
modeling. However, metabolic factors, including diabetes
status, play an important role [6–9]. Multiple studies
have used echocardiography to analyze the potential im-
pact of glycemic status on measures of LV mass and
geometric patterns. Although most studies found higher
values of LV mass in people with abnormal glucose me-
tabolism, these associations were often attenuated by the
presence of other traditional cardiovascular risk factors,
especially elevated blood pressure [10–15]. Moreover,
the prognostic utility of LV mass for CVD events in
people with diabetes also depends on other metabolic
factors [16–18].
These findings raise the question whether these mea-
surements of LV mass and geometric patterns are de-
tailed enough to describe the complex interplay between
glycemic status and blood pressure on cardiac structure.
Cardiac magnetic resonance imaging (CMR) has now
become the gold standard for the measurement of myo-
cardial mass and volumes [19, 20] and delivers a more
detailed characterization of cardiac morphology than
echocardiography, thereby allowing more precise in-
sights into the mechanisms of LV remodeling.
In our initial analyses, using CMR to derive measures
of LV geometry and function, we had observed an
increased myocardial mass in subjects with abnormal
glucose metabolism, but the difference disappeared after
adjustment for major cardiovascular risk factors [21].
We therefore aim to elucidate the impact of glycemic
status on regional LV remodeling and further analyze its
potential interaction with blood pressure.
Methods
Study sample
The study sample is a subsample of the second
follow-up of the population-based KORA (“Cooperative
Health Research in the Region of Augsburg”) S4 cohort
(KORA FF4). The major focus of the substudy is the
analysis of subclinical cardiovascular disease by
whole-body magnetic resonance imaging (MRI).
Recruitment and eligibility criteria for the KORA stud-
ies have been described elsewhere [22]. The KORA FF4
study was conducted between 2013 and 2014 and in-
cluded 2279 of the originally recruited 4261 KORA S4
participants. Of these, 400 subjects participated in the
MRI substudy who were eligible and willing to undergo
whole-body MRI. The detailed participant flow and
exclusion criteria have been described previously [21].
Additionally, we excluded 31 subjects with incomplete
measurements of any AHA segment due to low image
quality and subsequently excluded 10 subjects with vis-
ible Late Gadolinium Enhancement.
Covariate assessment
Glycemic status was defined as known diabetes, either
self-reported or defined by current use of glucose-lowering
medication, and in participants without known dia-
betes, it was determined by a standard 2-h oral
glucose tolerance test (OGTT). According to the 1999
WHO criteria [23], subjects with fasting serum
glucose levels ≥7.0 mmol/l or OGTT 2-h serum glu-
cose levels ≥11.1 mmol/l were also classified as hav-
ing diabetes. Isolated impaired fasting glucose (iIFG)
was defined as fasting glucose ≥6.1 but < 6.9 mmol/l
and 2-h glucose < 7.8 mmol/l. Isolated impaired glucose
tolerance (iIGT) was defined as fasting glucose <
6.1 mmol/l and 2-h glucose ≥7.8 but < 11.1 mmol/l.
Subjects with iIFG, iIGT or with both conditions were
classified as having prediabetes. Subjects with fasting
glucose < 6.1 mmol/l and 2-h glucose < 7.8 mmol/l were
considered controls.
Hypertension was defined as current antihypertensive
treatment and/or systolic/diastolic blood pressure above
140/90 mmHg. Prehypertension was defined as systolic/
diastolic blood pressure above 120/80 mmHg. Subjects
were classified as smokers if they reported current regular
or sporadic cigarette smoking. Cholesterol, serum glucose,
serum insulin and Hba1c were determined by standard
methods as described in Additional file 1: Text S1.
CMR outcome assessment
Magnetic resonance imaging was performed at a 3 Tesla
Magnetom Skyra (Siemens AG, Healthcare Sector,
Erlangen Germany) using a 18 channel body coil in
combination with the table-mounted spine matrix coil.
The whole-body MRI protocol comprised several se-
quences as described previously [21].
Imaging of cardiac function and morphology was
performed using cine steady-state free precession
(cine-SSFP) sequences in the short axis with a stack of
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10 layer and 25 phases per cardiac cycle as well as in a
4-chamber view (echo time 1.46 ms, repetition time
29.97 ms, in-plane voxel size 1.5 × 1.5 mm, flip angle
62–63°, field-of-view 297 × 360 mm, matrix size 240 ×
160 mm, slice thickness 8 mm).
The cine-SSFP sequences were then analyzed
semi-automatically using cvi42 software (Circle Cardio-
vascular Imaging, Calgary, Canada) by two readers un-
aware of the subject’s glycemic status and all other
clinical covariates. In the 4-chamber view, apex and base
of the LV were first manually selected, followed by auto-
matic border detection of the LV endocardial and epicar-
dial border in the short axis. Borders were corrected
manually, if necessary. The basal slice was selected when
at least 50 % of the LV cavity was surrounded by myo-
cardium at end-diastole. Papillary muscles and trabecu-
lations were excluded from the myocardial area and
included in the blood pool. To assess intraobserver
agreement, measurements of 25 randomly chosen sub-
jects were repeated by the first reader. Interobserver
agreement was assessed on 52 subjects who were mea-
sured by the first and the second reader. Intra- and In-
terobserver agreement were calculated by the Intraclass
Correlation Coefficient (ICC).
Mean wall thickness was measured at the end of
diastole for each segment according to the American
Heart Association (AHA) 16-segment model [24]. Mea-
surements of the single segments are visualized in a
polar plot according to glycemic status. For further stat-
istical analysis, segments are grouped according to level
(basal: AHA segments 1–6; mid-cavity: AHA segments
7–12; apical: AHA segments 12–16) and region (lateral:
AHA segments 5, 6, 11, 12 and 16; septal: AHA seg-
ments 2, 3, 8 and 9; anterior: AHA segments 1, 7 and
13; inferior: AHA segments 4, 10 and 15) [24].
Statistical analysis
Main demographic and cardiovascular characteristics of
the participants are reported as arithmetic means with
standard deviations for continuous variables and counts
and percentages for categorical variables. Differences in
wall thickness between the glycemic groups were
assessed by one-way ANOVA. A linear regression model
including glycemic status, age, sex, Body Mass Index
(BMI), systolic blood pressure, total cholesterol, use of
antihypertensive medication and smoking status was cal-
culated to determine the association of glycemic status
to the respective wall thickness variable. The same
model without adjustment for systolic blood pressure
was calculated for hypertension. Additionally, linear
regression models with multiplicative terms between
glycemic status and systolic blood pressure were com-
puted to discover any interaction effects.
As the MRI sample is a non-representative subsample
of a population based cohort, we used appropriate sam-
pling weights to render the sample more representative
of the full eligible underlying cohort. Weighting was
based on glycemic status, age and sex. Details of the
weighting procedure are presented in Additional file 1:
Text S2.
P-values < 0.05 were considered to denote statistical
significance. All analyses were done with R version 3.2.1
(R Core Team, Vienna, Austria).
The KORA FF4 study was approved by the ethics
committee of the Bavarian Chamber of Physicians,
Munich; the MRI substudy by the institutional review
board of the Ludwig-Maximilians-University Munich.
The investigations were carried out in accordance with
the Declaration of Helsinki, including written informed
consent of all participants.
Results
Study population
The sample of 359 subjects comprised 223 normogly-
cemic controls (62%), 92 subjects with prediabetes (26%)
and 44 subjects with diabetes (12%) as presented in
Table 1. Of those, 15 diabetes cases were diagnosed
based on the results of OGTT. In subjects with estab-
lished diabetes the median duration of diabetes was
7.0 years.
Intra- and Interobserver agreement
The ICCs for intraobserver and interobserver agree-
ment were 0.93 and 0.94 for mean wall thickness,
respectively. ICCs for single segments are presented
in Additional file 1: Figure S1.
Comparison of wall thickness according to glycemic status
Mean wall thickness of all AHA segments in the whole
sample was 9.1 mm (± standard deviation: 1.5 mm). The
polar plots in Fig. 1 display the wall thickness of the in-
dividual AHA segments for the three glycemic groups.
We found a gradual increase in wall thickness from
controls through prediabetes to diabetes for all classes of
segments grouped by level and region. The differences
between the glycemic groups were statistically significant
in univariate analysis for all analyzed segment classes
(Table 2).
Association of glycemic status and wall thickness
independent of confounding factors
After adjustment for additional covariates as detailed
above, prediabetes and diabetes were independently associ-
ated to increased wall thickness (prediabetes: β: 0.44 mm,
95%-CI: [0.12 mm, 0.75 mm], diabetes: β: 0.70 mm,
95%-CI: [0.23 mm, 1.17 mm]). Associations held true for
most segment classes according to level and region as
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presented in Table 3. The strongest associations were
found for the mid-cavity segments and the anterior
segments.
Effects of weighting
Additional file 1: Table S1 shows the characteristics of
the underlying eligible cohort that was used for the
calculation of sampling weights.
Comparing the MRI sample to the whole cohort, there
was an overrepresentation of subjects with prediabetes
(26% in the sample vs 12% in the cohort) and subjects
with diabetes (12% in the sample vs 10% in the cohort).
Additionally, the proportion of males was higher in the
MRI sample compared to the underlying cohort,
whereas mean age was similar.
Results of the unweighted analysis are presented in
Additional file 1: Table S2. Associations that were statis-
tically significant in the weighted analysis were also
significant in the unweighted analysis. The size of the es-
timates was comparable; however as sampling weights
Table 1 Demographic characteristics of study participants
All Control Prediabetes Type 2 diabetes
N = 359 N = 223 N = 92 N = 44
Age (years) 56.1 ± 9.1 54.3 ± 8.9 58.1 ± 8.8 61.4 ± 8.3
Male gender 205 (57.1%) 115 (51.6%) 58 (63.0%) 32 (72.7%)
BMI (kg/m2) 27.9 ± 4.8 26.5 ± 4.2 30.3 ± 4.6 30.2 ± 5.1
Systolic blood pressure (mmHg) 120.3 ± 16.9 116.5 ± 15.2 124.7 ± 15.5 130.1 ± 21.2
Diastolic blood pressure (mmHg) 75.3 ± 10.1 73.7 ± 9.2 78.0 ± 9.7 78.0 ± 13.2
Prehypertension 94 (26.2%) 61 (27.4%) 26 (28.3%) 7 (15.9%)
Hypertension 117 (32.6%) 45 (20.2%) 41 (44.6%) 31 (70.5%)
Fasting glucose (mmol/L) 5.7 ± 1.3 5.2 ± 0.4 5.9 ± 0.6 8.0 ± 2.3a
Fasting insulin (pmol/L) 65.4 ± 41.1 51.6 ± 26.7 86.9 ± 44.6 91.7 ± 60.0b
HbA1c (%) 5.6 ± 0.7 5.3 ± 0.3 5.6 ± 0.3 6.7 ± 1.4
Total cholesterol (mmol/L) 5.6 ± 1.0 5.6 ± 0.9 5.8 ± 0.8 5.5 ± 1.2
HDL cholesterol (mmol/L) 1.6 ± 0.5 1.7 ± 0.5 1.5 ± 0.4 1.4 ± 0.4
LDL cholesterol (mmol/L) 3.6 ± 0.9 3.6 ± 0.8 3.7 ± 0.8 3.5 ± 1.1
Triglycerides (mmol/L) 1.5 ± 1.0 1.2 ± 0.7 1.7 ± 1.0 2.3 ± 1.4
Smoking
Never-smoker 130 (36.2%) 88 (39.5%) 28 (30.4%) 14 (31.8%)
Ex-smoker 156 (43.5%) 87 (39.0%) 46 (50.0%) 23 (52.3%)
Smoker 73 (20.3%) 48 (21.5%) 18 (19.6%) 7 (15.9%)
Antihypertensive medication 85 (23.7%) 35 (15.7%) 28 (30.4%) 22 (50.0%)
Values are arithmetic means ± standard deviations for continuous variables and number of subjects (percentage of respective group) for categorical outcomes
aBased on N = 43 subjects with type 2 diabetes
bBased on N = 42 subjects with type 2 diabetes
Fig. 1 Left ventricular wall thickness (mm) of 16 AHA segments for control, prediabetes and diabetes group
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introduce additional variation in the data, confidence in-
tervals for the weighted analysis were wider than for the
unweighted analysis. Model diagnostics such as residual
distribution were similar between the weighted and un-
weighted analysis. Taken together, the evidence suggests
that the analytical model was correctly specified [25]
and although the weighted estimates are conceptually
more precise, as they relate to the underlying cohort, the
actual differences between weighted and unweighted
estimates were small.
Association of specific prediabetes subgroups and wall
thickness
We further differentiated prediabetes status into subjects
with iIFG (N = 35, 9.7% of total sample and 38.1% of
subjects with prediabetes), iIGT (N = 41, 11.4% of total
sample and 44.6% of subjects with prediabetes) and both
IFG + IGT (N = 16, 4.5% of total sample and 17.4% of sub-
jects with prediabetes). Though there were differences in
mean wall thickness according to segment classes between
the prediabetes subgroups there was no gradual increase
from iIFG to iIGT and IFG + IGT (See Additional file 1:
Figure S2 and Table S3).
Association of hypertension and wall thickness
independent of confounding factors
Prehypertension and hypertension were significantly asso-
ciated with increased wall thickness (prehypertension: β:
0.48 mm, 95%-CI: [0.17 mm, 0.79 mm], hypertension: β:
0.67 mm, 95%-CI: [0.31 mm, 1.02 mm]) after adjustment
for additional covariates. The strongest associations were
seen for the basal segments and the septal segments as
presented in Table 4. Notably, there was also a significant
association of hypertension to myocardial mass.
Interaction of glycemic status and blood pressure
As displayed in Fig. 2 we found no interaction of gly-
cemic status and systolic blood pressure for mean wall
thickness averaged over all segments. Marginal effects of
glycemic status, i.e. associations of prediabetes and
Table 2 Mean wall thickness grouped by level and region and myocardial mass
All Control Prediabetes P-value Type 2 diabetes P-value
N = 359 N = 223 N = 92 N = 44
Wall thickness (mm): arithmetic mean of
All segments 9.1 ± 1.5 8.8 ± 1.4 9.9 ± 1.4 < 0.001 10.5 ± 1.6 < 0.001
Basal segments 9.6 ± 1.6 9.4 ± 1.6 10.4 ± 1.6 < 0.001 10.8 ± 1.7 < 0.001
Mid segments 9.2 ± 1.8 8.9 ± 1.6 10.3 ± 1.8 < 0.001 10.9 ± 2.1 < 0.001
Apical segments 8.2 ± 1.5 8.0 ± 1.4 8.7 ± 1.5 < 0.001 9.3 ± 1.6 < 0.001
Lateral segments 9.8 ± 1.6 9.3 ± 1.5 10.3 ± 1.4 < 0.001 10.8 ± 1.8 < 0.001
Septal segments 9.1 ± 1.6 8.7 ± 1.5 9.7 ± 1.4 < 0.001 10.3 ± 1.6 < 0.001
Anterior segments 9.4 ± 1.9 8.8 ± 1.7 10.0 ± 1.7 < 0.001 10.8 ± 2.2 < 0.001
Inferior segments 9.4 ± 1.5 9.0 ± 1.5 9.9 ± 1.4 < 0.001 10.4 ± 1.4 < 0.001
Myocardial mass (g/m2) 70.0 ± 13.9 69.0 ± 13.6 72.3 ± 13.0 0.1 75.9 ± 16.0 0.019
P-values are obtained from one-way ANOVA and Bonferroni corrected for the repeated comparisons to the control group
Table 3 Association of glycemic status and wall thickness
Prediabetes Diabetes
Estimate 95%-CI P-value Estimate 95%-CI P-value
Wall thickness (mm): arithmetic mean of
All segments 0.44 [0.12, 0.75] 0.007 0.70 [0.23, 1.17] 0.004
Basal segments 0.33 [−0.05, 0.70] 0.087 0.51 [0.02, 0.99] 0.040
Mid segments 0.61 [0.20, 1.02] 0.004 0.86 [0.28, 1.45] 0.004
Apical segments 0.34 [−0.04, 0.73] 0.080 0.74 [0.23, 1.24] 0.005
Lateral segments 0.46 [0.09, 0.83] 0.014 0.65 [0.14, 1.16] 0.013
Septal segments 0.35 [0.05, 0.65] 0.023 0.64 [0.18, 1.10] 0.006
Anterior segments 0.52 [0.10, 0.93] 0.015 0.98 [0.38, 1.59] 0.002
Inferior segments 0.45 [0.11, 0.79] 0.009 0.58 [0.11, 1.04] 0.016
Myocardial mass (g/m2) −0.11 [−3.51, 3.28] 0.948 0.56 [−4.94, 6.07] 0.841
Estimates from linear regression models adjusted for age, sex, BMI, systolic blood pressure, total cholesterol, use of antihypertensive medication and smoking status
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Table 4 Association of hypertension and wall thickness
Prehypertension Hypertension
Estimate 95%-CI P-value Estimate 95%-CI P-value
Wall thickness (mm): arithmetic mean of
All segments 0.48 [0.17, 0.79] 0.003 0.67 [0.31, 1.02] < 0.001
Basal segments 0.63 [0.28, 0.98] < 0.001 0.83 [0.42, 1.24] < 0.001
Mid segments 0.35 [−0.01, 0.71] 0.057 0.70 [0.26, 1.14] 0.002
Apical segments 0.44 [0.02, 0.86] 0.043 0.38 [−0.01, 0.77] 0.060
Lateral segments 0.37 [0.03, 0.71] 0.036 0.52 [0.12, 0.92] 0.012
Septal segments 0.59 [0.29, 0.89] < 0.001 0.84 [0.48, 1.19] < 0.001
Anterior segments 0.44 [0.02, 0.86] 0.039 0.77 [0.34, 1.19] < 0.001
Inferior segments 0.51 [0.14, 0.88] 0.007 0.54 [0.16, 0.92] 0.006
Myocardial mass (g/m2) 3.18 [−0.02, 6.39] 0.053 6.16 [2.19, 10.12] 0.003
Estimates from linear regression models adjusted for age, sex, BMI, glycemic status, total cholesterol, use of antihypertensive medication and smoking status
Fig. 2 Marginal effects of glycemic status on wall thickness for multiplicative interactions with systolic blood pressure. Marginal effects indicate
the size of the association of the respective group (prediabetes or diabetes) with wall thickness for a specific value of systolic blood pressure.
Displayed are the marginal effects of prediabetes (solid line, dark grey) and diabetes (solid line, light grey) and the respective 95% confidence
interval for a grid of possible values of systolic blood pressure (range in data: 73–179.5 mmHg). The arithmetic mean is indicated by a dotted line.
The dashed line indicates the line of no effect
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diabetes with wall thickness for a specific value of
systolic blood pressure, remained constant over the
range of possible blood pressure values. However, for
basal segments, there was a decreasing marginal effect
of glycemic status with rising blood pressure, whereas
for mid-cavity and apical segments the marginal effect of
glycemic status was increasing with rising blood
pressure.
Discussion
Increased LV wall thickness is associated with a higher
risk for cardiovascular outcomes. Recent findings from
the Framingham study showed that a 0.1 unit increase in
relative wall thickness was accompanied by a 59%
increase in the hazard for cardiovascular disease [1]. A
detailed assessment of LV geometry based on regional
wall thickness can predict risk of incident cardiovascular
disease [26]. Given these implications, it is of major
importance to determine modifiable risk factors for
increased wall thickness.
Our findings from this cross-sectional study show that
(i) type 2 diabetes is associated to increased LV wall thick-
ness, independent of traditional cardiovascular risk factors
and especially independent of hypertension, (ii) the inde-
pendent association of abnormal glucose homeostasis to
cardiac structure is already present in prediabetes, (iii) in-
dividual LV segments are differently affected by hyperten-
sion and glycemic status. Thereby, we could demonstrate
that the more specific evaluation of CMR derived regional
LV wall thickness unveils associations that cannot be de-
tected when assessing LV mass alone.
Our results therefore support and extend findings
from other established population-based studies. In the
Atherosclerosis Risk in the Community (ARIC) study,
Skali et al. found that mean and relative LV wall thick-
ness were elevated in subjects with diabetes independent
of systolic blood pressure. To a certain extent, wall
thickness was already increased in subjects with predia-
betes [27]. In the Framingham Offspring Cohort,
Velageti et al. [28] found an increasing CMR derived
relative wall thickness across glycemia categories. After
multivariable adjustment, the association remained
significant in men. In the Multiethnic Study of Athero-
sclerosis (MESA), an association between CMR-derived
LV mass and diabetes was found that was independent
of blood pressure; however no measurements of seg-
mental wall thickness were taken [29]. On the other
hand, Bertoni et al. measured mid-cavity segments and
found an increasing wall thickness for Caucasian sub-
jects with normal glucose metabolism to subjects with
iIFG and type 2 diabetes. The differences were not sig-
nificant after adjustment for other cardiovascular risk
factors [30]. Another study found an association of gly-
cemic status to LV mass, but not to (relative or mean)
wall thickness [31]. In our sample, we showed that the
increased LV mass in subjects with diabetes was attribut-
able to hypertension but there are independent regional
associations of diabetes and blood pressure in segmental
wall thickness.
Regarding the prediabetic state, recent evidence from
the CARDIA study implies that longer exposure to ab-
normal glucose tolerance, longer duration of diabetes,
and early onset of diabetes leads to more unfavorable re-
modeling [32]. Analyses from the Strong Heart Study
demonstrated increased LV mass in Native Americans
with impaired glucose tolerance, however the finding
was less definitive for measures of wall thickness [33].
Our findings corroborate that prediabetes, defined as ei-
ther iIGT, iIFG or IFG + IGT, is independently associated
to increased wall thickness. Our sample size was prob-
ably too small to detect gradual effects of these different
prediabetic groups.
Disentangling the associations of blood pressure and
glycemic status proves to be complicated. In the Strong
Heart Study, LV mass of subjects with diabetes but with-
out hypertension was significantly lower compared to
those subjects with both conditions, whereas relative
wall thickness was not different [34]. In the HyperGEN
study comprising only hypertensive subjects, diabetes
was independently associated to increased LV mass [35].
A recent Chinese study suggested additive effects of dia-
betes and hypertension to LV remodeling [36]. Although
blood pressure reduction appears to be an effective way
of lowering the risk of cardiovascular disease in hyper-
tensive patients with increased LV mass, [37] these treat-
ments do not seem to be as effective in patients with
diabetes [38]. In our study, we found a decreasing mar-
ginal effect of both prediabetes and diabetes with rising
blood pressure for the basal segments, whereas the mar-
ginal effect for apical and mid segments was increasing.
Thus we could further characterize the complex inter-
play of blood pressure and glycemic status and its im-
pact on cardiac geometry.
The exact mechanisms of impaired glucose metabolism
on LV geometry remain to be identified. Increased LV stiff-
ness, induced by an accumulation of collagen and ad-
vanced glycation end products and subsequent fibrosis in
diabetic cardiomyopathy have been suggested to contrib-
ute to LV remodeling [39, 40]. Also, a decreased myocar-
dial perfusion reserve in subjects with diabetes induced by
an impaired myocardial blood flow has been shown to be
correlated with LV torsion and strain [41]. Recent findings
imply that myocardial steatosis, excess storage of cardiac
triglycerides, and impaired myocardial energetics are asso-
ciated with concentric LV remodeling [42]. However, our
study is limited in this respect as it cannot explain the
pathophysiological mechanisms behind the association of
glycemic status on regional LV geometry.
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The values of LV wall thickness reported here, as
measured by short-axis cine SSFP, substantially exceed
the reference values according to the 16-segment model
suggested by other groups [43, 44]. These reference
values have been obtained from healthy subjects with a
low-risk profile for developing cardiovascular disease,
excluding smokers, and people with hypertension or
diabetes. Given the major impact of these risk factors on
wall thickness, it is plausible that our study found larger
values for the control group.
For this nested cross-sectional study, we used a
well-characterized population-based cohort. Highly
standardized measurements and validation allowed us
to precisely define covariates and glycemic status.
Furthermore, using adequate sampling weights we
were able to relate our results to the full underlying
cohort.
Limitations of our study include its cross-sectional
design that precludes causal inference. Further longi-
tudinal follow-up of this study sample is mandated to
determine the prognostic potential of segmental wall
thickness.
Conclusion
Our findings highlight the role of glycemic status as a
potential risk factor and implicate prediabetes as un-
favorably associated to LV wall thickness. Measurements
of regional wall thickness provides a more precise pic-
ture than assessing overall myocardial mass. Delaying or
halting progression from impaired fasting glucose to dia-
betes might prevent further thickening of the ventricular
walls and subsequent cardiovascular complications.
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